Herceptin.net - Herceptin in metastatic BC

Proven survival benefit in first-line metastatic breast cancer

Herceptin is established as the foundation of care for women with HER2-positive MBC.

Benefits of Herceptin as second-line therapy for metastatic breast cancer

Evidence suggests that treatment with Herceptin beyond disease progression can extend survival.

Dosage and administration

Recommendations for dosage and administration of Herceptin

EU approval and labelling information

Herceptin is approved for the treatment of women with early and metastatic HER2-positive breast cancer and patients with HER2-positive metastatic gastric cancer.

Disclaimer: Herceptin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.herceptin.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
Privacy statement
Legal statement
Contact